ConductScience.org, home
Genes
API referenceFor AI assistants

Gene · 406999

MIR217: microRNA 217

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. MIR217: microRNA 217. Genes, record 406999. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/406999

On this page

Gene

Symbol
MIR217
HGNC
Name
microRNA 217
HGNC
NCBI Gene ID
406999
NCBI Gene
HGNC ID
HGNC:31594
HGNC
Ensembl
ENSG00000207548
NCBI Gene
Aliases
MIRN217, hsa-mir-217, miR-217, mir-217
NCBI Gene
Type
ncRNA
NCBI Gene

Proteins0

Reviewed human proteins whose Swiss-Prot entry states the gene.

None in this release.

Patents0

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

None in this release.

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants525

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleMIR217 papersNewest fiscal year
P30CA016058Cancer Center Support Grant52025
P30CA016672Cancer Center Support Grant52025
P30CA033572Cancer Center Support Grant32025
P30CA076292Moffitt Cancer Center Support Grant22025
P30CA086862Cancer Center Support Grant22025
R01HL076485Engineering Vascularized Cardiac Muscle22025
U01CA214254Exosome-based microRNA biomarkers for Non-invasive and Early Detection of Pancreatic Cancer22025
U54MD012392RCMI Center for Health Disparities Research22025
ZIAAG000393Influence of Post-transcriptional Gene Regulation on Cell Senescence and Aging22025
ZIABC011115Epigenetic Mechanisms of Gene Expression in Thoracic Malignancies22025

1 to 10 of 525Source NIH's project files

See all 525 nih grants

Papers2,102

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Comprehensive preclinical evaluation of second-generation miRNA-regulated Coxsackievirus B3-BHP: Potent antitumor efficacy and safety.Mol Ther Oncol202642733473PubTator, text miningPubMed
Retraction: microRNA-217 suppressed epithelial-to-mesenchymal transition through targeting PTPN14 in gastric cancer.Biosci Rep202642565213PubTator, text miningPubMed
Correction: miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5.PLoS One202642475271PubTator, text miningPubMed
LINC01614 favors breast cancer progression through the regulation of miR-217/FN1 and mediation in PI3K/AKT signal pathway.Transl Cancer Res202642445377PubTator, text miningPubMed
Long non-coding RNAs as molecular links and circulating biomarkers between type 2 diabetes and colorectal cancer: focus on shared signaling pathways, epigenetic regulation, and ubiquitination mechanisms.
Front Mol Biosci202642256316PubTator, text miningPubMed
Urinary exosomes aggravate diabetic kidney disease by inducing podocyte ferroptosis via the miR-217/SIRT1/Nrf2 pathway.J Cell Commun Signal202642039924PubTator, text miningPubMed
MicroRNA, MicroRNA-lncRNA and MicroRNA-Circular RNA axes, and exosomal MicroRNAs: driving exercise-induced cardioprotection in heart failure.Front Cell Dev Biol202641960190PubTator, text miningPubMed
Tumor exosomes impact functional hallmarks of cancer.Cancer Metastasis Rev202641912733PubTator, text miningPubMed
Crosstalk between KRAS and miRNAs in pancreatic cancer: Opportunities for its diagnosis, prognosis and therapeutic intervention (Review).Int J Oncol202641860028PubTator, text miningPubMed
Emerging role of epigenetic mechanisms in glaucoma and their translational potential.Front Genet202641809128PubTator, text miningPubMed

1 to 10 of 2,102

See all 2,102 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/406999

GET https://conductscience.org/api/genes/v1/406999/grants?page=2

API referenceFor AI assistants